中国临床保健杂志2016，Vol.19Issue(4)：352-354,3.DOI:10.3969/J.issn.1672-6790.2016.04.005
磷酸西格列汀联合二甲双胍治疗2型糖尿病的临床疗效
Clinical effect of phosphate sitagliptin combined with metformin in treatment of type 2 diabetes mellitus
姚璐 1武云涛 1张薇 1夏常泉 1田国祥 1王晓兵1
作者信息
摘要
Abstract
Objective To observe the efficacy and safety of phosphoric acid combined with metformin in pa-tients with type 2 diabetes mellitus untreated or without any therapy in 12 weeks.Method Ninety type 2 diabetes pa-tients had not received prior treatment or without any therapy in 12 weeks for their diabetes were randomly divided into sitagliptin phosphate combined with metformin group,metformin group,phosphate sitagliptin group.Three groups were compared after 16weeks of glycosylated hemoglobin (HbA1 c),fasting blood glucose (FBG),2 hour postprandial blood glucose (PBG)and side effect of medicine.Result After 16 weeks of treatment,The FBG,PBG and HbA1 c in phos-phoric acid sitagliptin combined with metformin group were lower than those in phosphate sitagliptin group (P <0.05). Compared with the metformin group,the PBG and HbA1 c decreased significantly in combined treatment group;,FBG de-creased in combined treatment group but the differences between the two groups was not significant (P >0.05).The in-cidence rate of hypoglycemia,diarrhea,nausea and vomiting gastrointestinal adverse event were similar among three groups,there was not statistically significant(P >0.05).None of the patients had abnormality in liver and kidney func-tion,acute pancreatitis and other adverse events.Conclusion Sitagliptin phosphate combined with metformin is superior to metformin and phosphate sitagliptin monotherapy in the hypoglycemic effects with low hypoglycemia and gastrointesti-nal adverse reactions.关键词
糖尿病,2 型/二甲双胍/二肽基肽酶Ⅳ抑制剂Key words
Diabetes Mellitus,Type 2/Metformin/Dipeptidyl-peptidase IV Inhibitors分类
医药卫生引用本文复制引用
姚璐,武云涛,张薇,夏常泉,田国祥,王晓兵..磷酸西格列汀联合二甲双胍治疗2型糖尿病的临床疗效[J].中国临床保健杂志,2016,19(4):352-354,3.
